{"nctId":"NCT00955747","briefTitle":"Naturlose (D-Tagatose) Efficacy Evaluation Trial","startDateStruct":{"date":"2007-04"},"conditions":["Type 2 Diabetes"],"count":494,"armGroups":[{"label":"Sugar Substitute Splenda","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Sugar Substitute Splenda"]},{"label":"Tagatose","type":"EXPERIMENTAL","interventionNames":["Drug: Tagatose"]}],"interventions":[{"name":"Tagatose","otherNames":["Naturlose"]},{"name":"Sugar Substitute Splenda","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetics in accordance with WHO.\n* Male and female patients, between 18 and 75 years of age.\n* Diabetic patients who are not on medication for the disease. Patients may be treated with diet and exercise.\n* Normal blood creatine clearance and normal liver function test results.\n* BMI less than or equal to 45kg/m2.\n\nExclusion Criteria:\n\n* Treatment with sulfonylurea (e.g., Glyburide, Glipizide, Glimepiride, Chlorpropamide, Tolazamide, Acetohexamide, or Tolbutamide), TZDs, metformin, acarbose, Byetta, insulin, and any antidiabetic medications within the prior 3 months.\n* Therapy with beta-blockers or thiazide diuretics within the prior 3 months.\n* Pregnancy, breastfeeding, or intention of becoming pregnant or judged to be using inadequate contraceptive measure.\n* Documented gastrointestinal disease, or taking of medications likely to alter gut motility or absorption.\n* Receiving any investigational drug within 30 days of the baseline visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin A1C Level From Baseline","description":"The primary efficacy variable will be the change in HbA1c level from baseline. Changes from baseline in HbA1c level at each visit will be assessed with the use of linear model(ANCOVA) to adjust for any baseline difference, as well as the stratification factor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.07"},{"groupId":"OG001","value":"-0.11","spread":"0.07"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":207},"commonTop":["Diarrhoea","Flatulence","Gastrointestinal sounds abnormal","abdominal pain","Frequent bowel movements"]}}}